Summary In a study of 154 neuroblastomas, loss of heterozygosity (LOH) was observed on lp (13%, 19/143), llq (19%, 11/59), 14q (15%, 15/97), 17p (5%, 5/105) and 17q (17%, 9/52). We also found an increase in NM23HJ copy number in 14% (13/95) of neuroblastomas. All except one tumour with an increased copy number stained positive with anti-NM23H1 monoclonal antibody. Event-free survival (EFS) was significantly shorter in 19 patients with LOH on lp than in 128 without (41% vs 77% 4 year EFS, P=0.0093), and in 13 patients with increased NM23H1 copy numbers than in 82 with normal copy numbers of the gene (61% vs 84% 4 year EFS, P=0.0103). LOH on llq, 14q or 17q did not affect EFS. Most tumours with LOH on lp, increased NM23HI copy numbers or MYCN amplification occurred in patients aged 12 months or more, those with advanced stage disease, and those who showed near diploidy or pseudodiploidy. However, LOH on lp was found in only 1 of the 13 tumours with increased NM23HJ copy numbers, and MYCN amplification of four copies occurred in only one other such tumour. These findings suggest that the increased NM23HJ copy number may be a predictor for poor prognosis, independent of LOH on lp, and probably also of MYCN amplification.
Molecular genetic studies of neuroblastoma have suggested the presence of a tumour-suppressor gene on lp36 (Fong et al., 1989 (Fong et al., , 1992 Weith et al., 1989) . We and other investigators have recently reported that another tumour-suppressor gene on lp32-lp34 may be closely associated with a biologically aggressive subtype of neuroblastoma (Takeda et al., 1994; Schleiermacher et al., 1994) . Furthermore, two other tumoursuppressor genes associated with the development and/or progression of neuroblastoma are thought to be located on 1 lq and 14q (Fong et al., 1992; Srivatsan et al., 1993; Suzuki et al., 1989; Takayama et al., 1992) .
The NM23 gene was identified as a metastasis-suppressor gene by differential hybridisation between two murine melanoma sublines with low and high metastatic potential (Steeg et al., 1988) . The gene codes for the nucleoside diphosphate kinase protein, and is located on 17q21-22 (Gilles et al., 1991; Varesco et al., 1992) . Reduced expression of NM23 was associated with lymph node metastases and poor prognosis in breast cancer (Bevilacqua et al., 1989) . In contrast, overexpression, mutation and amplifiction of NM23 were reported in aggressive neuroblastomas (Hailat et al., 1991; Leone et al., 1993; Chang et al., 1994) .
We studied the loss of heterozygosity (LOH) on Ip, 1llq, 14q, 17p and 17q in 154 neuroblastomas and found LOH on Ip, 1 lq, 14q and 17q in incidences ranging between 13% and 19%, but that on 17p, where a tumour-suppressor gene TP53 is located (Human Gene Mapping, 1991) , in only 5%. In addition, we examined NM23H1 copy markers in 95 neuroblastomas and found that there was an increase in the copy number in 14% of the tumours. Event-free survival (EFS) was examined between patients with LOH on Ip, 1 lq, 14q or 17q and those without, and between patients with increased NM23HI copy numbers and those without. The results indicated that only allelic loss on lp and increased NM23HJ copy number predicted an adverse treatment outcome. Molecular studies Genomic DNA was extracted from the tumour tissue and peripheral blood using standard phenol/chloroform procedures. An aliquot of 3 -8 ig of DNA from each sample was digested with appropriate restriction enzymes, electrophoresed through 0.6 -0.8% agarose gels and transferred onto nylon membranes (Hybond N+, Amersham, Tokyo) by alkaline blottings.
Materials and methods
The 22 probes used to detect allelic loss included D1S7 (MS1) on lp, D1IS146 (pHBI59), D1IS29 (L7), CD3D (pPGBC9), CD3E (pDJ4), PBGD (PBGD), Dl1S147 copy number as an increase in the radioactivity of the NM23HJ fragments of tumour tissue relative to both D81B2.0 and D14S23 to more than 150% compared with that of the corresponding fragments of normal tissue (Figure 1 ).
PCR -SSCP (polymerase chain reaction -single strand conformation polymorphism) analysis was performed on three tumours that showed LOH on 17p, using pairs of primers to detect mutations of exons 5, 6, 7 and 8 of TP53 (Murakami et al., 1991) . The same filters were successively hybridised with the NM23HJ, D81B2.0 and D14S23 probes. The radioactivity of the NM23HJ fragments relative to that of the D81B2.0 or D14S23 fragment was compared in tumour and normal tissues. The NM23HJ copy numbers of tumour 797 relative to that of the normal tissue were 2.8 and 2.0 when D81B2.0 and D14S23 were used as internal controls of one copy respectively, and those of tumour 1126 were 1.9 and 1.6 respectively.
(HBI18P1), DIIS286 (phage 8-10), DlIS382 (CJ52.12), D11S383 (CJ52.15) on llq, INS (pHINS6.0) and D11S151 (p56H2.4) on lip, ANG (ANG), D14S13 (pMLJ14), D14S1 (pAWl0l), D14S17 (pEFZ18.2), D14S16 (pTHH37), D14S23 (cKKA39), D14S19 (pHHH208) and D14S20 (pMCOC12) on 14q and D17S30 (pYNZ22) on 17p (Human Gene Mapping, 1991) . The NM23HJ probe, specifically hybridising to the NM23HJ gene (Okada et al., 1994) , was used for detection of allelic loss on 17q and determination of the NM23HJ copy number. D81B2.0 [an intron fragment from MTG8 on chromosome 8 with no restriction fragment length polymorphisms (RFLP) site for Bglll] and D14S23 were used as an internal control for one copy. Presence or absence of MYCN amplification was examined with the probe NB-19-21, and probe no. 8 or ERBB2 was used as an internal control. The DNA probes were labelled with [32P]dCTP by the random priming method (Feinberg and Vogelstein, 1983) . Hybridisation was carried out as described previously (Takeda et al., 1994) .
Autoradiography and quantification of radioactivity were performed using a bioimage analyser (FUJIX BAS 2000) . The radioactivity of an RFLP fragment relative to that of another fragment of the same sample was compared in tumour and normal tissues. We defined allelic loss as a reduction in the relative radioactivity of one fragment of tumour tissue to less than 50% compared with that of the corresponding fragment of normal tissue.
The radioactivity of the NM23HJ fragments relative to that of the D81B2.0 and D14S23 fragments was compared between tumour and normal tissues. We defined an increased NM23H1
Immunohistochemical studies Avidin-biotin complex (ABC) immunoperoxidase assay was performed on 4 yim sections from formalin-fixed, paraffinembedded tissues. Tissue sections were deparaffinised, rehydrated and exposed to 0.3% hydrogen peroxide in methanol to eliminate endogenous peroxidase activity. Sections were incubated with monoclonal anti-human NM23H 1 antibody (Seikagaku, Tokyo, Japan) diluted 1:300 in phosphate-buffered saline (PBS) for 18 h at 4°C. The specificity of the antibody was proved by immunoprecipitation and immunoblotting (Urano et al., 1993) . The ABC assay was performed using CSA kits (Dako, CA, USA). The end-products were visualised by treating the sections with diaminobenzidine tetrahydrochloride. Negative controls were performed with normal mouse or rabbit serum instead of the primary antibody. The slides were scored without knowledge of the NM23HJ gene analysis and before compilation of the clinical data. Three categories were used in scoring the slides: strong staining (+), weak staining (±), no staining (-) of tumour cells. Only tumours with strong staining were considered to have a positive reaction.
Chromosome studies The tumour tissue was minced with scissors and was cultured in plastic flasks containing ES medium (Nissui, Seiyaku, Tokyo) with 15% fetal calf serum. The cells were harvested within 96 h from the start of culture. Bone marrow cells were cultured for 24 h in plastic flasks containing RPMI-1640 medium with 20% fetal calf serum, and were harvested. Chromosomes were analysed by regular Giemsa staining and Q-and/or G-banding techniques. We defined abnormal clones and chromosome ploidies according to ISCN (1991) . When we found only normal diploid metaphase cells in tumour tissues, the examination was considered to have failed to detect malignant mitotic cells and, hence, to be inadequate.
Statistical analyses
The EFS for each group of patients was estimated by the Kaplan -Meier method (Kaplan and Meier, 1958) on the data updated on 30 April, 1995; and differences in EFS curves were assessed using the generalised Wilcoxon and log-rank tests (Gehan, 1965; Peto and Peto, 1972 DliS383 and DlIS146 respectively, the commonly deleted region on 1 lq was distal to DlIS 146 and proximal to Dl 1S383. Ninety-six of the 107 patients were informative at one or more loci on chromosome 14q, and 15 of the 96 informative The NM23HJ copy number was examined in 95 patients, and 13 of the 95 (14%) showed increased copy numbers ranging from 1.5 to 4.4 (Figure 1 ).
Immunohistochemical staining with anti-NM23HI monoclonal antibody NM23H1 protein expression was demonstrated in 11 of the 29 patients whose tumour tissues were examined (Figure 4) IpLOH_b   128  82  46  78  31  19  66  26  36  19  5  62  42  7  121  NM23HI +cd  13  3  10  5  4  4  2  2  9  7  1  2  3  1  12  NM23H1_ c,d 82   52  30  47  23  12  41  17  24  14  5  40  23  11  71 aMass screening: +, undergone the mass screening with a positive result; -, undergone the mass screening with a negative result; N, not undergone the mass screening. 'There is a significant difference in the incidence of patients under .12 months of age (P = 0.0006), in the incidence of patients found by mass screening (P= 0.0136), in the stage distribution (P= 0.0142), in the ploidy distribution (P= 0.0071) and in the incidence of patients with MYCN amplification (P<0.0001) between the patients with LOH on Ip and those without. cNM23HJ +, with an increased NM23HJ copy number; NM23HJ -, with a normal NM23HJ copy number. dThere is a significant difference in the incidence of patients under 12 months of age (P= 0.0129), in the stage distribution (P= 0.0158) and in the ploidy distribution (P= 0.0121) between the patients with an increased NM23HI copy number and those without. Ploidies and karyotypes of tumours with an increased NM23H1 copy number (Tables III and IV) Modal chromosome numbers were determinable in 10 of the 13 tumours with increased NM23H1 copy number; seven had near-diploidy or pseudodiploidy, two had near-triploidy and the other had hypotetraploidy. Karyotypes were successfully analysed in three of the ten tumours (Table IV ). All three tumours had hypo-or pseudodiploidy; two of them apparently had a normal pair of chromosomes 17, and the 16% (15/96) , 5% (5/105) and 17% (9/ 52) of neuroblastomas respectively. In previous studies on neuroblastomas, the incidence of LOH on lp ranged from 25% to 89%, on llq was 28%, on 14q ranged from 22% to 40% and on 17p was 0% (Fong et al., 1989 (Fong et al., , 1992 Weith et al., 1989; Takeda et al., 1994; Schleiermacher et al., 1994; Srivatsan et al., 1993; Suzuki et al., 1989; Takayama et al., 1992) . The incidence of LOH on 17q has not been reported. The incidences of LOH on Ip, 1 lq or 14q in our series were lower than those previously reported on these three chromosomal regions. The different incidences may have been caused by the inclusion in our series of a large number of patients found by mass screening. Our study defined the locations of putative tumour-suppressor genes of 1 lq and 14q in the region distal to DlIS146 (llql3) and proximal to D11S383 (l1q24-25) and in the region distal to D14S13 and proximal to D14SI respectively. Both of the D14 loci were mapped in 14q32, and the distance between D14S13 and D14SI is estimated at 8 Mb (Nakamura et al., 1989) .
We also found increased NM23HI copy numbers in 14% (13/95) of neuroblastomas. The results were confirmed by immunohistochemical staining using anti-NM23HI monoclonal antibody. The previous study reported increased NM23HJ copy numbers in 23% (7/31) of neuroblastomas (Leone et al., 1993) . The same study reported no increase in the copy number of NM23H2, which is located next to NM23HI on 17q21 -22. Another study showed 17q polysomy in 38% (20/53) of neuroblastomas using polymorphic DNA markers on 17q other than NM23HJ (Caron, 1995) . Our cytogenetic study on the three tumours showed no polysomy of 17q, and suggested that the limited chromosomal region including the NM23HJ locus may have amplified in the tumours.
We compared EFS of different groups of patients classified by presence or absence of LOH in each of the four chromosomal regions (i.e. lp, 1 lq, 14q and 17q) in the tumour and by presence or absence of an increased NM23HI copy number. Only LOH on lp and an increased NM23HI copy number proved to be predictors for adverse treatment outcome. Most tumours with an increased NM23HJ copy number occurred in patients aged 12 months or more with advanced stage disease and who showed near-diploidy or pseudodiploidy; these characteristics are similar to those tumours with LOH on lp or with MYCN amplification (Takeda et al., 1994) . However, LOH on lp was found in only 1 of the 13 tumours with an increased NM23HJ copy number, and MYCN amplification of four copies was found in only one other tumour (Table III) . These findings indicate that an increased NM23HJ copy number may be a predictor for poor prognosis independent of LOH on lp and probably also of MYCN amplification. Thus, by using various genetic markers, including the copy numbers of MYCN and NM23H1 and presence or absence of LOH on lp, we may be able to predict the prognosis of neuroblastoma patients more precisely than otherwise. Therapy should be intensified in patients with positive results for these specified genetic markers.
